|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1998-9-10
|
|
pubmed:abstractText |
The aim of this study was to determine the clinical activity and toxicity of a novel chemotherapy combination regimen of gemcitabine plus cisplatin, administered every three weeks, in patients with advanced non-small-cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
457-9
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:9636840-Adult,
pubmed-meshheading:9636840-Aged,
pubmed-meshheading:9636840-Antimetabolites, Antineoplastic,
pubmed-meshheading:9636840-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9636840-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:9636840-Cisplatin,
pubmed-meshheading:9636840-Deoxycytidine,
pubmed-meshheading:9636840-Drug Administration Schedule,
pubmed-meshheading:9636840-Female,
pubmed-meshheading:9636840-Humans,
pubmed-meshheading:9636840-Lung Neoplasms,
pubmed-meshheading:9636840-Male,
pubmed-meshheading:9636840-Middle Aged,
pubmed-meshheading:9636840-Neoplasm Staging,
pubmed-meshheading:9636840-Prognosis,
pubmed-meshheading:9636840-Survival Rate,
pubmed-meshheading:9636840-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.
|
|
pubmed:affiliation |
Division of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
